Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Cash from Operations (2025 - 2026)

Updated

Aktis Oncology (AKTS) recorded Cash from Operations of -$26.05 million in Q3 2026, compared with -$15.22 million a year earlier.

Analysis

Aktis Oncology (AKTS) Cash from Operations (2025 - 2026) Analysis & Trends

On a TTM basis, Aktis Oncology's Cash from Operations came in at -$86.12 million as of Sep 30, 2026; for FY2025, it was -$64.13 million.

  • Across earlier years, Cash from Operations came in at $14.76 million in FY2024.
  • Per Business Quant, the preceding three quarters came in at -$20.59 million (Q2 2026), -$24.24 million (Q1 2026) and -$15.24 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 11.40 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 7.72 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 7.61 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 6.56 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 4.67 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 4.24 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 5.04 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 5.38 Bn
10 Aktis Oncology 895.95 Mn 335.72 Mn - -26.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -26.05 Mn
Jun 30, 2026 -20.59 Mn
Mar 31, 2026 -24.24 Mn
Jun 30, 2025 -16.18 Mn
Mar 31, 2025 -17.48 Mn
API Access

Aktis Oncology Cash from Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-operations&ticker=AKTS&period=max&api_key=YOUR_API_KEY